2-(Benzo[d][1,3]dioxol-5-yl)-6-chloroimidazo[1,2-a]pyridine

Catalog No. :
ACZTEP386
CAS No. :
168837-35-2
Molecular Formula :
C14H9ClN2O2
Molecular Weight :
272.69

IUPAC Name:2-(benzo[d][1,3]dioxol-5-yl)-6-chloroimidazo[1,2-a]pyridine

2-(Benzo[d][1,3]dioxol-5-yl)-6-chloroimidazo[1,2-a]pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg95%$121.00Login to see priceInquiryInquiry
10mg95%$147.00Login to see priceInquiryInquiry
250mg95%$379.00Login to see priceInquiryInquiry
1g95%$706.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(Benzo[d][1,3]dioxol-5-yl)-6-chloroimidazo[1,2-a]pyridine
IUPAC Name2-(benzo[d][1,3]dioxol-5-yl)-6-chloroimidazo[1,2-a]pyridine
MDL No.MFCD04126134
Molecular FormulaC14H9ClN2O2
Molecular Weight272.69
SMILESClC1=CN2C(C=C1)=NC(C3=CC=C(OCO4)C4=C3)=C2
InChI KeyAWNGFBUYGOWSNY-UHFFFAOYSA-N
Synonym2-BENZO[1,3]DIOXOL-5-YL-6-CHLORO-IMIDAZO[1,2-A]PYRIDINE;2-(1,3-BENZODIOXOL-5-YL)-6-CHLOROIMIDAZO[1,2-A]PYRIDINE;2-(2H-1,3-benzodioxol-5-yl)-6-chloroimidazo[1,2-a]pyridine;Imidazo[1,2-a]pyridine, 2-(1,3-benzodioxol-5-yl)-6-chloro-;2-(Benzo[d][1,3]dioxol-5-yl)-6-chloroimidazo[1,2-a]pyridine
CAS No.168837-35-2

Synthetic Route by SureRoute

1. ACZTEP386 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACRHBJ690 route compound structure diagram
    ACRHBJ69094839-07-3 In Stock
  4. Then
  5. ACZTEP386 route product structure diagram
    ACZTEP386168837-35-2
Inquiry

2. ACZTEP386 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACIHBG416 route compound structure diagram
    ACIHBG41694838-82-1 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZTEP386 route product structure diagram
    ACZTEP386168837-35-2
Inquiry

Comments (0)